Investigational therapies superior to standard-of-care in double-exposed CLL Presented ByDr Meghan Thompson, Memorial Sloan Cancer Center, NY, USA ConferenceASH 2021 4 February, 2022 11:36
Ibrutinib continues to outperform chemoimmunotherapy in patients with treatment-naïve CLL ExpertDr Jennifer Woyach, Ohio State University, OH, USA TrialPhase 3, Alliance A041202 ConferenceASH 2021 3 February, 2022 23:22